10113 related articles for article (PubMed ID: 18159896)
1. Genetic mutations involved in melanoma: a summary of our current understanding.
High WA; Robinson WA
Adv Dermatol; 2007; 23():61-79. PubMed ID: 18159896
[TBL] [Abstract][Full Text] [Related]
2. [Molecular biology of familial cases of human melanoma].
Kit OI; Vodolazhsky DL; Timoshkina NN; Przhedetsky YV; Khokhlova OV
Vopr Onkol; 2015; 61(6):889-97. PubMed ID: 26995975
[TBL] [Abstract][Full Text] [Related]
3. [Genotypic hypervariability of melanoma: a therapeutic challenge].
Dalle S; Martin-Denavit T; Thomas L
Med Sci (Paris); 2006 Feb; 22(2):178-82. PubMed ID: 16457759
[TBL] [Abstract][Full Text] [Related]
4. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Pho L; Grossman D; Leachman SA
Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187
[TBL] [Abstract][Full Text] [Related]
5. Germline MC1R variants and BRAF mutant melanoma.
Hacker E; Hayward NK
J Invest Dermatol; 2008 Oct; 128(10):2354-6. PubMed ID: 18787543
[TBL] [Abstract][Full Text] [Related]
6. High- and low-penetrance cutaneous melanoma susceptibility genes.
Fargnoli MC; Argenziano G; Zalaudek I; Peris K
Expert Rev Anticancer Ther; 2006 May; 6(5):657-70. PubMed ID: 16759158
[TBL] [Abstract][Full Text] [Related]
7. Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients.
Vergani E; Frigerio S; Dugo M; Devecchi A; Feltrin E; De Cecco L; Vallacchi V; Cossa M; Di Guardo L; Manoukian S; Peissel B; Ferrari A; Gallino G; Maurichi A; Rivoltini L; Sensi M; Rodolfo M
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573422
[TBL] [Abstract][Full Text] [Related]
8. [Genetic predisposition in cutaneous melanoma].
Avilés JA; Lázaro P
Actas Dermosifiliogr; 2006 May; 97(4):229-40. PubMed ID: 16801015
[TBL] [Abstract][Full Text] [Related]
9. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
[No Abstract] [Full Text] [Related]
10. Melanoma genetics: an update on risk-associated genes.
Udayakumar D; Tsao H
Hematol Oncol Clin North Am; 2009 Jun; 23(3):415-29, vii. PubMed ID: 19464594
[TBL] [Abstract][Full Text] [Related]
11. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
12. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
Levin T; Mæhle L
Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
[TBL] [Abstract][Full Text] [Related]
13. Multiple primary melanomas versus single melanoma of the head and neck: a comparison of genetic, diagnostic, and therapeutic implications.
Pollio A; Tomasi A; Pellacani G; Ruini C; Mandel VD; Fortuna G; Seidenari S; Ponti G
Melanoma Res; 2014 Jun; 24(3):267-72. PubMed ID: 24638154
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
Read J
Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
[TBL] [Abstract][Full Text] [Related]
15. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
[TBL] [Abstract][Full Text] [Related]
16. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.
Gallagher SJ; Thompson JF; Indsto J; Scurr LL; Lett M; Gao BF; Dunleavey R; Mann GJ; Kefford RF; Rizos H
Neoplasia; 2008 Nov; 10(11):1231-9. PubMed ID: 18953432
[TBL] [Abstract][Full Text] [Related]
17. Management of familial melanoma and nonmelanoma skin cancer syndromes.
Santillan AA; Cherpelis BS; Glass LF; Sondak VK
Surg Oncol Clin N Am; 2009 Jan; 18(1):73-98, viii. PubMed ID: 19056043
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
19. [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma].
Avril MF; Bahadoran P; Cabaret O; Caron O; de la Fouchardière A; Demenais F; Desjardins L; Frébourg T; Hammel P; Leccia MT; Lesueur F; Mahé E; Martin L; Maubec E; Remenieras A; Richard S; Robert C; Soufir N; Stoppa-Lyonnet D; Thomas L; Vabres P; Bressac-de Paillerets B
Ann Dermatol Venereol; 2015 Jan; 142(1):26-36. PubMed ID: 25600792
[TBL] [Abstract][Full Text] [Related]
20. Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study.
Thomas NE; Kanetsky PA; Edmiston SN; Alexander A; Begg CB; Groben PA; Hao H; Busam K; Ollila DW; Berwick M; Conway K
J Invest Dermatol; 2010 May; 130(5):1463-5. PubMed ID: 20043015
[No Abstract] [Full Text] [Related]
[Next] [New Search]